Hepcludex (Bulevirtide)

Hepcludex is a prescription antiviral medication whose active ingredient is bulevirtide, supplied as a 2 mg per vial injection solution for subcutaneous administration. It belongs to the viral entry inhibitor class and is marketed in the European Union for the treatment of chronic hepatitis D infection. The drug works by blocking the NTCP receptor, preventing hepatitis B and D viruses from entering human liver cells effectively.

Hepcludex is indicated for patients with chronic hepatitis D virus (HDV) infection, typically in combination with nucleos(t)ide analogues for hepatitis B virus suppression.

- Used to treat adults with confirmed chronic HDV infection. - Administered as a subcutaneous injection, usually once daily or as prescribed. - May be considered for patients who have not responded adequately to standard hepatitis B therapy. - Intended for use under specialist supervision in hepatology or infectious disease settings. - Can be part of a comprehensive antiviral regimen targeting both HBV and HDV.

The safety profile of Hepcludex includes a range of observed adverse events, which are categorized by frequency and severity.

Common: - Injection site reactions such as pain, redness, swelling, or induration lasting up to several days. - Mild headache or fatigue that usually resolves without intervention. - Transient elevation of liver enzymes (ALT/AST) observed during early treatment phases. - Nausea, mild abdominal discomfort, or loss of appetite that are generally self‑limited.

Serious: - Severe allergic reactions, including anaphylaxis, characterized by rash, swelling, respiratory distress, or hypotension. - Significant liver injury or hepatitis flare, indicated by marked increases in ALT/AST and bilirubin. - Persistent or worsening thrombocytopenia that may require clinical monitoring.

Before initiating Hepcludex, clinicians should evaluate several precautionary factors to ensure safe use.

- Assess baseline liver function tests and monitor regularly throughout therapy. - Evaluate for a history of hypersensitivity to bulevirtide or any component of the formulation. - Use caution in patients with pre‑existing liver disease or decompensated cirrhosis. - Pregnancy status should be determined; the drug’s safety in pregnancy is not established. - Counsel patients on proper subcutaneous injection technique to minimize local reactions. - Consider renal function, although bulevirtide is not primarily renally excreted. - Review concomitant antiviral regimens to avoid overlapping toxicities.

Hepcludex may interact with other medicines; understanding potential interactions helps optimize treatment outcomes.

Avoid: - Co‑administration with other viral entry inhibitors that target the same NTCP pathway. - Concurrent use of drugs known to cause severe hypersensitivity reactions.

Use with caution: - Nucleos(t)ide analogues for hepatitis B, as combined therapy may affect liver enzyme levels. - Immunosuppressive agents, which could alter the immune response to viral infection. - Medications metabolized by hepatic pathways that may be influenced by changes in liver function. - Herbal supplements that affect liver enzymes, such as St John’s wort.